Research ArticleOriginal Article
Open Access

Clinical and laboratory characteristics of idiopathic inflammatory myositis in Saudi patients

A retrospective study in a single tertiary centre

Fahidah Alenzi, Jawaher Alotaibi, Manal Alnasser and Fahdah Alokaily
Saudi Medical Journal May 2023, 44 (5) 492-497; DOI: https://doi.org/10.15537/smj.2023.44.5.20220213

References

  1. 1.↵
    1. Bohan A,
    2. Peter JB.
    Polymyositis and Dermatomyositis. N Engl J Med 1975; 292: 344–347.
    OpenUrlCrossRefPubMedWeb of Science
  2. 2.↵
    1. Sanner H,
    2. Gran J-T,
    3. Sjaastad I,
    4. Flato B.
    Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford) 2009; 48: 1541–1547.
    OpenUrlCrossRefPubMedWeb of Science
  3. 3.↵
    1. Betteridge Z,
    2. Tansley S,
    3. Shaddick G,
    4. Chinoy H,
    5. Cooper RG,
    6. New RP, et al.
    Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J Autoimmun 2019; 101: 48–55.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. McHugh NJ,
    2. Tansley SL.
    Autoantibodies in myositis. Nat Rev Rheumatol 2018; 14: 290–302.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Sato S,
    2. Hoshino K,
    3. Satoh T,
    4. Fujita T,
    5. Kawakami Y,
    6. Fujita T, et al.
    RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 2009; 60: 2193–2200.
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Satoh M,
    2. Tanaka S,
    3. Ceribelli A,
    4. Calise SJ,
    5. Chan EKL.
    A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clinical Reviews in Allergy and Immunology 2017; 52: 1–19.
    OpenUrl
  7. 7.↵
    1. Lundberg I,
    2. Nennesmo I,
    3. Hedfors E.
    A clinical, serological, and histopathological study of myositis patients with and without anti-RNP antibodies. Semin Arthritis Rheum 1992: 127–138.
  8. 8.
    1. Clarke AE,
    2. Bloch DA,
    3. Medsger Jr TA,
    4. Oddis C V.
    A longitudinal study of functional disability in a national cohort of patients with polymyositis/dermatomyositis. Arthritis Rheum 1995; 38: 1218–1224.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    1. Nakashima R.
    Clinical significance of myositis-specific autoantibodies. Immunol Med 2018; 41: 103–112.
    OpenUrl
  10. 10.↵
    1. Malaviya AN
    . 2017 EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: little emphasis on autoantibodies, why? Ann Rheum Dis. 2018; 77: e77–e77.
    OpenUrlFREE Full Text
  11. 11.↵
    1. Sultan SM,
    2. Ioannou Y,
    3. Moss K,
    4. Isenberg DA.
    Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatol 2002; 41: 22–26.
    OpenUrlCrossRefPubMedWeb of Science
  12. 12.↵
    1. Lundberg IE,
    2. Forbess CJ.
    Mortality in idiopathic inflammatory myopathies. Clin Exp Rheumatol 2008; 26: S109.
    OpenUrlPubMedWeb of Science
  13. 13.↵
    1. Danko K,
    2. Ponyi A,
    3. Constantin T,
    4. Borgulya G,
    5. Szegedi G.
    Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine (Baltimore) 2004; 83: 35–42.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    1. Lundberg IE,
    2. Tjärnlund A,
    3. Bottai M,
    4. Werth VP,
    5. Pilkington C,
    6. de Visser M, et al.
    2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol 2017; 69: 2271–2282.
    OpenUrl
  15. 15.↵
    1. Ng KP,
    2. Ramos F,
    3. Sultan SM,
    4. Isenberg DA.
    Concomitant diseases in a cohort of patients with idiopathic myositis during long-term follow-up. Clin Rheumatol 2009; 28: 947–953.
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    1. Al-Ballaa SR,
    2. Al-Dalaan AN,
    3. El-Ramahi KM,
    4. Al-Janadi MA,
    5. Al-Shaikh A,
    6. Bahabri S.
    Pattern of adult onset of polymyositis and dermatomyositis and association with malignancy. Ann Saudi Med 1993; 13: 525–529.
    OpenUrlPubMed
  17. 17.↵
    1. Chen Z,
    2. Hu W,
    3. Wang Y,
    4. Guo Z,
    5. Sun L,
    6. Kuwana M.
    Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis/dermatomyositis. Clin Rheumatol 2015; 34: 1627–1631.
    OpenUrl
  18. 18.↵
    1. Srujith CH,
    2. Mohanasundaram K,
    3. Jagadeesan M,
    4. Halleys KE,
    5. Kannan R,
    6. Sivasubramanian K, et al.
    A study on demographic pattern of idiopathic inflammatory myopathies in a tertiary care hospital. Int J Adv Med 2019; 6: 236.
    OpenUrl
  19. 19.↵
    1. Ramesha KN,
    2. Kuruvilla A,
    3. Sarma PS,
    4. Radhakrishnan V V
    . Clinical, electrophysiologic, and histopathologic profile, and outcome in idiopathic inflammatory myositis: An analysis of 68 cases. Ann Indian Acad Neurol 2010; 13: 250.
    OpenUrlPubMed
  20. 20.↵
    1. Mugii N,
    2. Hasegawa M,
    3. Matsushita T,
    4. Hamaguchi Y,
    5. Oohata S,
    6. Okita H, et al.
    Oropharyngeal dysphagia in dermatomyositis: associations with clinical and laboratory features including autoantibodies. PLoS One 2016; 11: e0154746.
    OpenUrl
  21. 21.↵
    1. Noguchi E,
    2. Uruha A,
    3. Suzuki S,
    4. Hamanaka K,
    5. Ohnuki Y,
    6. Tsugawa J, et al.
    Skeletal muscle involvement in anti synthetase syndrome. JAMA Neurol 2017; 74: 992–999.
    OpenUrl
  22. 22.↵
    1. Clark KEN,
    2. Isenberg DA.
    A review of inflammatory idiopathic myopathy focusing on polymyositis. Eur J Neurol 2018; 25: 13–23.
    OpenUrl
  23. 23.↵
    1. Douglas WW,
    2. Tazelaar HD,
    3. Hartman TE,
    4. Hartman RP,
    5. Decker PA,
    6. Schroeder DR, et al.
    Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001; 164: 1182–1185.
    OpenUrlCrossRefPubMedWeb of Science
  24. 24.↵
    1. Ji S,
    2. Zeng F,
    3. Guo Q,
    4. Tan G,
    5. Tang H,
    6. Luo Y, et al.
    Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study. Chin Med J (Engl) 2010; 123: 517–522.
    OpenUrlPubMed
  25. 25.↵
    1. Mustafa KN,
    2. Dahbour SS.
    Clinical characteristics and outcomes of patients with idiopathic inflammatory myopathies from Jordan 1996-2009. Clin Rheumatol 2010; 29: 1381–1385.
    OpenUrlPubMed
  26. 26.
    1. Bronner IM,
    2. van der Meulen MFG,
    3. de Visser M,
    4. Kalmijn S,
    5. van Venrooij WJ,
    6. Voskuyl AE, et al.
    Long-term outcome in polymyositis and dermatomyositis [Internet]. Ann Rheum Dis 2006; 65: 1456–1461.
    OpenUrlAbstract/FREE Full Text
  27. 27.
    1. Marie I,
    2. Hachulla E,
    3. Cherin P,
    4. Dominique S,
    5. Hatron PY,
    6. Hellot MF, et al.
    Interstitial lung disease in polymyositis and dermatomyositis. Clin Chest Med 2002; 47: 614–622.
    OpenUrl
  28. 28.↵
    1. Uthman I,
    2. Vazquez-Abad D,
    3. Senecal JL.
    Distinctive features of idiopathic inflammatory myopathies in French Canadians. Semin Arthritis Rheum 1996; 26: 447–458.
    OpenUrlCrossRefPubMedWeb of Science
  29. 29.↵
    1. Danko K,
    2. Ponyi A,
    3. Constantin T,
    4. Borgulya G,
    5. Szegedi G.
    Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine 2004; 83: 35–42.
    OpenUrlCrossRefPubMedWeb of Science
  30. 30.
    1. Airio A,
    2. Kautiainen H,
    3. Hakala M.
    Prognosis and mortality of polymyositis and dermatomyositis patients. Clin Rheumatol 2006; 25: 234–239.
    OpenUrlCrossRefPubMedWeb of Science
  31. 31.
    1. Torres C,
    2. Belmonte R,
    3. Carmona L,
    4. Gomez-Reino FJ,
    5. Galindo M,
    6. Ramos B, et al.
    Survival, mortality and causes of death in inflammatory myopathies. J Autoimmun 2006; 39: 205–215.
    OpenUrl
  32. 32.
    1. Sigurgeirsson B,
    2. Lindelöf B,
    3. Edhag O,
    4. Allander E.
    Risk of cancer in patients with dermatomyositis or polymyositis. N Engl J Med 1992; 326: 363–367.
    OpenUrlCrossRefPubMedWeb of Science
  33. 33.↵
    1. Sparsa A,
    2. Liozon E,
    3. Herrmann F,
    4. Ly K,
    5. Lebrun V,
    6. Soria P, et al.
    Routine vs Extensive Malignancy Search for Adult Dermatomyositis and Polymyositis. Arch Dermatol 2002;138.
  34. 34.↵
    1. Tembe AG,
    2. Ramteke S,
    3. Joshi VR,
    4. Balakrishnan C.
    Dermatomyositis/polymyositis associated with malignancy: our experience with ten patients and review of relevant literature. Int J Rheum Dis 2008; 11: 269–273.
    OpenUrl
  35. 35.
    1. Chen Y-J,
    2. Wu C-Y,
    3. Huang Y-L,
    4. Wang C-B,
    5. Shen J-L,
    6. Chang Y-T.
    Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther 2010; 12: R70.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Ravelli A,
    2. Trail L,
    3. Ferrari C,
    4. Ruperto N,
    5. Pistorio A,
    6. Pilkington C, et al.
    Long-term outcome and prognostic factors of juvenile dermatomyositis: A multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken) 2010; 62: 63–72.
    OpenUrl
  37. 37.↵
    1. Allenbach Y,
    2. Benveniste O.
    Acquired necrotizing myopathies. Curr Opin Neurol 2013; 26: 554–560.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Dobloug C,
    2. Garen T,
    3. Bitter H,
    4. Stjärne J,
    5. Stenseth G,
    6. Grøvle L, et al.
    Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis 2015; 74: 1551–1556.
    OpenUrlAbstract/FREE Full Text
  39. 39.↵
    1. Nuño L,
    2. Joven B,
    3. Carreira P,
    4. Maldonado V,
    5. Larena C,
    6. Llorente I, et al.
    Registro de pacientes con miopatía inflamatoria de la Sociedad Madrileña de Reumatología: análisis descriptivo.
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords